Biological therapy became available for psoriasis with the introduction of alefacept at the
beginning of this century. Up to then, systemic treatment options comprised small molecule …

Psoriasis is considered as a T‐cell‐mediated inflammatory skin disease which is
characterized by hyperproliferation and poor differentiation of epidermal keratinocytes …

Background Biologic therapies such as adalimumab, a tumour necrosis factor antagonist,
are safe and effective in the treatment of moderate to severe chronic plaque psoriasis …

Solid lipid nanoparticles (SLN) were developed by using Precirol ATO 5 as the solid core of
the particles for topical psoralen delivery. Nanostructured lipid carriers (NLC) consisting of …

BACKGROUND: Tumor necrosis factor is pivotal in the pathogenesis of psoriasis.
Adalimumab is a fully human monoclonal immunoglobulin G1 antibody that neutralizes …

Background: Psoriasis is often associated with the risk of physical disability, social
discomfort and psychological disorders. Objectives: The aim of this study was to investigate …

In patients with moderate-to-severe psoriasis, remission can be difficult to achieve and
sustain. Both acutely acting and long-term maintenance agents are needed. Speed and …

Background: In previous phase II studies, alefacept significantly improved psoriasis and was
well tolerated. The clinical response to alefacept was durable. Objective: Our purpose was to …

OBJECTIVES: To evaluate the clinical effectiveness, safety, tolerability and cost-
effectiveness of etanercept and efalizumab for the treatment of moderate to severe chronic …

Objective: Our purpose was to demonstrate the efficacy of the 308-nm excimer laser for
treatment of psoriasis. Methods: This study was a multicenter open trial from 5 dermatology …